← Back to All US Stocks

EDAP Stock Analysis 2026 - EDAP TMS SA AI Rating

EDAP Nasdaq Electromedical & Electrotherapeutic Apparatus CIK: 0001041934
Recently Updated • Analysis: Mar 24, 2026 • SEC Data: 2026-03-24
HOLD
5% Conf
Pending
Analysis scheduled

📊 EDAP Key Takeaways

Revenue: N/A
Net Margin: N/A
Free Cash Flow: N/A
Current Ratio: N/A
Debt/Equity: N/A
EPS: $0.00
AI Rating: HOLD with 5% confidence

Is EDAP a Good Investment? Thesis Analysis

Claude

Unable to conduct fundamental analysis due to unavailable financial data. All critical income statement, balance sheet, cash flow, and profitability metrics are missing, making it impossible to assess financial health, profitability trends, or growth quality.

Why Buy EDAP? Key Strengths

Claude
  • -No strengths identified

EDAP Investment Risks to Consider

Claude
  • ! Complete absence of financial data in SEC filings
  • ! No revenue, earnings, or cash flow information available
  • ! Inability to assess liquidity, solvency, or operational performance

Key Metrics to Watch

Claude
  • * Revenue and gross profit trends
  • * Operating cash flow and free cash flow generation
  • * Balance sheet strength and debt levels

EDAP Financial Metrics

Revenue
N/A
Net Income
N/A
EPS (Diluted)
$0.00
Free Cash Flow
N/A
Total Assets
N/A
Cash Position
N/A

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

EDAP Profitability Ratios

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA N/A
FCF Margin N/A

EDAP vs Healthcare Sector

How EDAP TMS SA compares to Healthcare sector averages

Net Margin
EDAP 0.0%
vs
Sector Avg 12.0%
EDAP Sector
ROE
EDAP 0.0%
vs
Sector Avg 15.0%
EDAP Sector
Current Ratio
EDAP 0.0x
vs
Sector Avg 2.0x
EDAP Sector
Debt/Equity
EDAP 0.0x
vs
Sector Avg 0.6x
EDAP Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is EDAP Overvalued or Undervalued?

Based on fundamental analysis, EDAP TMS SA has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
N/A
Sector avg: 15%
Net Profit Margin
N/A
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
N/A
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

EDAP Balance Sheet & Liquidity

Current Ratio
N/A
Quick Ratio
N/A
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
N/A

EDAP Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

EDAP SEC 10-K & 10-Q Filing Analysis

Access official SEC EDGAR filings for EDAP TMS SA (CIK: 0001041934)

📋 Recent SEC Filings

Date Form Document Action
Mar 18, 2026 8-K f8k_031826.htm View →
Feb 12, 2026 8-K f8k_021226.htm View →
Jan 12, 2026 8-K f8k_011226.htm View →
Feb 10, 2022 SC 13G Edap.txt View →
Apr 28, 2021 SC 13G d114352dsc13g.htm View →

Frequently Asked Questions about EDAP

What is the AI rating for EDAP?

EDAP TMS SA (EDAP) has an AI rating of HOLD with 5% confidence, based on fundamental analysis of SEC EDGAR filings.

What are EDAP's key strengths?

Claude: .

What are the risks of investing in EDAP?

Claude: Complete absence of financial data in SEC filings. No revenue, earnings, or cash flow information available.

What is EDAP's revenue and growth?

EDAP TMS SA reported revenue of N/A.

Does EDAP pay dividends?

EDAP TMS SA does not currently pay dividends.

Where can I find EDAP SEC filings?

Official SEC filings for EDAP TMS SA (CIK: 0001041934) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is EDAP's EPS?

EDAP TMS SA has a diluted EPS of $0.00.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is EDAP a good stock to buy right now?

Based on our AI fundamental analysis in March 2026, EDAP TMS SA has a HOLD rating with 5% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is EDAP stock overvalued or undervalued?

Valuation metrics for EDAP: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy EDAP stock in 2026?

Our dual AI analysis gives EDAP TMS SA a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is EDAP's free cash flow?

EDAP TMS SA's operating cash flow is N/A, with capital expenditures of N/A.

How does EDAP compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).

Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 24, 2026 | Data as of: 2026-03-24 | Powered by Claude AI